Search
Showing results for "early lung health"
Aboriginal families and communities have endured the imposition of countless ‘solutions’ and had to live with the consequences of these ineffective initiatives. Those consequence are sadly evident in the unrelenting gap in outcomes for Aboriginal kids, compared with other Australian children.
By participating in ORIGINS, you are contributing to one of the largest and most comprehensive birth cohort studies ever.
A main challenge identified by youth during exercise and sport is the lack of knowledge and awareness around type 1 diabetes (T1D) particularly in community sport settings. Working with youth living with T1D, parents and community sport coaches, our team has developed resources for the T1D and sporting community. This study was to evaluate the acceptability and usability of the resources.
The Opportunity The ORIGINS Project is a longitudinal pregnancy cohort, following 10,000 families over a decade, to improve child and adult outcomes
Influenza vaccination is recommended to protect mothers and their infants from influenza infection. Few studies have evaluated the health impacts of in utero exposure to influenza vaccine among children more than six months of age.
The burden of IgE-mediated food allergy in Australian born children is reported to be among the highest globally. This illness shares risk factors and frequently coexists with asthma, one of the most common noncommunicable diseases of childhood.
This fellowship will assist Associate Professor Palmer in her large-scale food allergy prevention trials.
The proportion of births via cesarean section (CS) varies worldwide and in many countries exceeds WHO-recommended rates. Long-term health outcomes for children born by CS are poorly understood, but limited data suggest that CS is associated with increased infection-related hospitalisation. We investigated the relationship between mode of birth and childhood infection-related hospitalisation in high-income countries with varying CS rates.
Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma.
We demonstrate a distinct gut virome profile in infants of mothers with type 1 diabetes, which may influence health outcomes later in life